Home | Publications | Diseases place holder
place holder place holder

Diseases

The Future of Metabolomics

Building competitive advantage in drug discovery, clinical development and diagnostics

Publication Date   August 2006
Publisher   Business Insights
Product Type   Report
Pages   156
ISBN Number   not applicable
Product Code   RBI103
Ask a question about this product?

Price £1,495.00

approximately: $2,640 | €1,896

Summary


Metabolomics - the new 'omics' - is a dynamic and emerging field, joining genomics, transcriptomics and proteomics in enabling an integrative systems biology approach to drug discovery and development. Although metabolomics is still at an early evolutionary stage it is forecast that over the next decade the biopharma industry will apply this technology more widely in drug development and data obtained will be used in drug filing and optimizing the lifecycle management of marketed drugs. The Future of Metabolomics provides detailed insight into the effective use of metabolomics throughout drug discovery, preclinical development and clinical trials. The report also highlights the use of metabolomics in maximizing and sustaining revenues post-marketing and in the development of clinical diagnostics. Use up-to-date case studies to understand current and future directions in the application of metabolomics to drug discovery and development, explore potential cost savings, and recognize lucrative partnering opportunities in this fast moving field.

Content


  • Executive Summary
    • Introduction
    • Platform Technologies In Metabolomics
    • Regulatory And Standardization Issues
    • Metabolomics In Drug Discovery & Preclinical Development
    • Metabolomics In Clinical Drug Development
    • The Role Of Metabolomics For Marketed Drugs
    • Metabolomics In Diagnostics And Health Screening
    • Market Size, Alliances, Acquisitions And Future Directions
  • Chapter 1 Introduction
    • Summary
    • What Is Metabolomics?
    • The Metabolome
    • Metabolomics' Relationship With Other 'Omics Technologies
    • Uses Of Metabolomics In Drug Discovery And Development
    • Advantages Of Metabolomics
    • Challenges To The Field Of Metabolomics
    • Conclusions
  • Chapter 2 Platform Technologies In
    • Metabolomics
    • Summary
    • Introduction
    • Technologies For Metabolomics
    • Iv
    • Mass Spectrometry (Ms)
    • Nuclear Magnetic Resonance Spectroscopy (Nmr)
    • Ms Versus Nmr
    • Other Spectroscopic And Chromatographic Techniques
    • Fourier-Transform Infrared Spectroscopy (Ftir)
    • Electrochemical Array
    • Emerging Technologies
    • Technology Developments
    • Metabolomics In Individual Cells
    • Experimental Design And Analysis
    • Data Transformation, Peak Deconvolution And Quantification
    • Metabolite Identification
    • Data Mining And Analysis: Chemometrics
    • Databases For Metabolic Pathway Analysis
    • Conclusions
  • Chapter 3 Regulatory And Standardization
    • Issues
    • Summary
    • Introduction
    • Regulatory Issues
    • Us Food And Drug Administration
    • European Medicines Agency (Emea) And The Japanese Ministry Of Health
    • And Welfare (Mhlw)
    • Standardization In Metabolomics
    • Incentives For Pharma
    • Conclusions
  • Chapter 4 Metabolomics In Drug Discovery& Preclinical Development
    • Summary
    • Introduction
    • Target Identification And Validation
    • Lead Prioritization
    • Pharmacology, Efficacy And Mechanism Of Action Studies
    • Case Study: Lipomics Technologies Inc
    • Case Study: Sidmap
    • Preclinical Studies For Non-Target Effects
    • Case Study: Icoria - Liver Toxicity Biomarkers
    • Case Study: Pfizer - Biomarkers Of Vasculitis
    • Case Study: Glaxosmithkline - Peroxisome Proliferation
    • Case Study: The Consortium For Metabonomics Technology (Comet)
    • Strengths And Limitations Of Metabolomics For Preclinical Research
    • Metabolomics In Systems Biology
    • Case Study: The Liver Toxicity Biomarker Study (Ltbs)
    • Conclusions
  • Chapter 5 Metabolomics In Clinical Drug
    • Development
    • Summary
    • Introduction
    • Patient Stratification And Pharmacogenomics
    • Clinical Pharmacometabolomics
    • Case Study: Bayer's Biomarkers For Response To Sorafenib Treatment
    • Metabolomics For Biomarker Discovery
    • Case Study: Phenomenome Discoveries Colorectal Cancer Biomarker
    • Case Study: Biomarkers Of Asthma From The University Of Alberta, Canada
    • The Challenge Of Human Variation
    • Conclusions
  • Chapter 6 The Role Of Metabolomics For
    • Marketed Drugs
    • Summary
    • Introduction
    • Product Differentiation
    • Case Study: Metabolon Inc And Bristol-Myers-Squibb Study Protease
    • Inhibitors
    • Product Lifecycle Management
    • Seeking New Indications
    • Case Study: Drug Repositioning By Genelogic
    • Researching Efficacy And Safety Problems
    • Case Study: Sidmap Predicts Gleevec Resistance
    • Drug And Transplant Monitoring
    • Case Study: Toxicodynamic Monitoring Of Immunosuppressants With Nmr
    • Case Study: Transplant Monitoring With Metabolomics
    • Conclusions
  • Chapter 7 Metabolomics In Diagnostics And
    • Health Screening
    • Summary
    • Introduction
    • Diagnostic Applications Of Metabolomics
    • Case Study: A Nmr-Based Diagnostic Test For Atherosclerosis
    • Case Study: A Diagnostic Test For Coronary Heart Disease
    • Case Study: A Metabolic Signature For Motor Neuron Disease
    • Case Study: Novel Biomarkers For Pre-Eclampsia
    • Case Study: The Magnetic Resonance Diagnostics Centre
    • Metabolomics For Population Screening
    • Case Study: Newborn Screening By Pediatrix Screening
    • Case Study: The Molpage Consortium
    • Conclusions
  • Chapter 8 Market Size, Alliances,
    • Acquisitions And Future Directions
    • Summary
    • Introduction
    • Saving Costs In Preclinical Drug Development
    • Saving Costs In Clinical Studies
    • Cost Effective Diagnostics
    • Key Metabolomics Companies And Academic Groups
    • Patent Position
    • Current Use Of Metabolomics In The Pharma Industry
    • The Metabolomics Market
    • Conclusions
  • Chapter 9 Appendix
    • Index
    • Bibliography
    • Endnotes
  • List Of Figures
    • Figure 1.1: Established Biochemical Pathways
    • Figure 1.2: Number Of Publications In Metabolomics, 1997-2005
    • Figure 1.3: The Human Metabolome
    • Figure 1.4: The 'Omics Technologies
    • Figure 1.5: Preclinical And Clinical Uses Of Metabolomics
    • Figure 2.6: Mass Spectrometry - A Summary
    • Figure 2.7: Nmr Spectroscopy
    • Figure 2.8: 1h Nmr Spectrum Of Urine Showing Functional Windows
    • Figure 2.9: Analysis Of Metabolomics Data
    • Figure 2.10: Examples Of Pca And Pls-Da Plots For Biomarker Discovery
    • Figure 2.11: Algorithms For Metabolomic Data Analysis
    • Figure 2.12: Metabolic Pathway Map: Biosynthesis Of Isoleucine
    • Figure 3.13: The Metabolomics Standardization Initiative
    • Figure 4.14: Metabolomics For Target Identification
    • Figure 4.15: Metabolon Case Study: Prioritization Of Lead Anti-Infective Compounds
    • Figure 4.16: Metabolomics For Toxicity Screening In Preclinical Drug Development
    • Figure 4.17: Principal Component Analysis Of Urine From Rats Treated With A Vasculitis Causing Compound
    • Figure 4.18: Operation Of The Comet Expert System For Predicting Main Organ Toxicity
    • Figure 4.19: Organization Of The Liver Toxicity Biomarker Study
    • Figure 5.20: Drug Development: Cumulative Cost Per Step Including Failures
    • Figure 5.21: Uses Of Metabolomics In Clinical Drug Development
    • Figure 5.22: Pharmacogenomic Approach To Patient Stratification In Clinical Trials
    • Figure 5.23: Patient Stratification: Value For Business And Public Health From The Use Of Pharmacogenomics In Herceptin Development
    • Figure 5.24: The Pharmacometabonomic Hypothesis Tested In Rats
    • Figure 5.25: Metabolomic Biomarker Discovery Protocol For Sorafenib
    • Figure 5.26: Biomarker Discovery At Phenomenome Discoveries Inc: Colorectal Cancer Example
    • Figure 5.27: Nmr Spectra Of Urine From Asthmatic Patients And Healthy Individuals
    • Figure 6.28: Metabolite Expression In Adipocytes By Five Protease Inhibitors
    • Figure 6.29: Metabolic Flux Analysis Using Carbon-13 Labelled Glucose As A Tracer
    • Figure 7.30: Relationship Between Ldl Particles And Ldl Cholesterol, Hdl Cholesterol And Triglycerides
    • Figure 7.31: Classification Of Coronary Artery Disease With Metabolomics
    • Figure 7.32: Metabolomic Analysis Of Data From Patients With Als And Controls
    • Figure 7.33: Diagnosis Of Community Acquired Pneumonia Using Metabolomics: The Mrdc Project
    • Figure 7.34: Pca And Metabolite Correlation Maps For Diagnosis Of Pulmonary Diseases From The Magnetic Resonance Diagnostics Centre
    • Figure 8.35: Better Data Improves Productivity
    • Figure 8.36: The Biology-Centric Drug Discovery Process
  • List Of Tables
    • Table 1.1: Advantages Of Metabolomics
    • Table 2.2: Comparison Of Nmr Vs. Ms For Metabolomics Applications
    • Table 2.3: Publicly Available Databases Of Metabolite Spectra
    • Table 2.4: Commercial Metabolite Identification Software
    • Table 2.5: Metabolomics Data Analysis Software
    • Table 2.6: Publicly Available Databases Of Metabolic Pathways
    • Table 4.7: Strengths And Limitations Of Metabolomics In Toxicology
    • Table 4.8: Metabolites Often Detected In Metabolomic Studies
    • Table 6.9: Number Of Metabolites Up- And Down-Regulated By Five Protease Inhibitors
    • Table 6.10: A Summary Of Statistically Significant Metabolomic Or Metabolite Measurements Relevant To Organ Transplantation Or Organ Dysfunction
    • Table 7.11: Metabolic Disorders Identified By The Pediatrix Stepone Test
    • Table 7.12: Partners In The Molpage Consortium
    • Table 8.13: Leading Suppliers And Service Companies In Metabolomics
    • Table 8.14: Bioinformatics/Chemometrics Companies Interested In Metabolomics
    • Table 8.15: Key Academic Centers For Metabolomics Research
    • Table 8.16: Number Of Patents Issued By Metabolomics-Based Biomarker Discovery And Service Companies
    • Table 8.17: Patents For Metabolomic Methods
    • Table 8.18: Patents Applying Metabolomic Technologies To Drug/Diagnostic Development
    • Table 8.19: Alliances Between Leading Metabolomics Companies And Pharma, Academia And Platform Developers
    • Table 8.20: Alliances Between Leading Metabolomics Companies And Pharma, Academia And Platform Developers
    • Table 8.21: Metabolomics Market Size And Forecast: 2005-2012 ($Bn)